Inhaled iloprost for severe pulmonary hypertension.
By H. Olschewski, G. Simonneau, N. Galiè, T. Higenbottam, R. Naeije, Lewis J. Rubin, S. Nikkho, R. Speich, M. Hoeper, J. Behr and 13 more. New England Journal of Medicine, 2002
1,622 citations recorded by the source corpus.
Subfields: Physiology, Pulmonary and Respiratory Medicine
View Paper: https://www.semanticscholar.org/paper/632e73cf1ca97ea31154d0c38150a8cf6e9fe3c7
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Pulmonary and Respiratory Medicine
Citations in the corpus
- Complications of right heart catheterization procedures in patients with pulmonary hypertension in experienced centers. (2006, background): “In addition, repeat right heart catheterizations are often used to assess hemodynamic efficacy of novel treatments (3–10).”
- Randomized study of adding inhaled iloprost to existing bosentan in pulmonary arterial hypertension. (2006, methodology): “In a randomized, placebo-controlled study (Aerosolized Iloprost Randomized [AIR] study), inhaled iloprost was demonstrated to be efficacious therapy for PAH based on a combined endpoint of improvement in modified New York Heart Association (NYHA) functional class, 10% or greater improvement in 6-min”
- Pulmonary arterial hypertension (2013, background): “The pulmonary vasodilating effects of inhaled iloprost lasts nearly 45 minutes, therefore six to nine inhalations daily are needed, with each of them requiring approximately 30 minutes [223,224].”